Literature DB >> 33524540

Resistin induces cardiac fibroblast-myofibroblast differentiation through JAK/STAT3 and JNK/c-Jun signaling.

Rajvir Singh1, Ravinder K Kaundal1, Baoyin Zhao1, Rihab Bouchareb1, Djamel Lebeche2.   

Abstract

Cardiac fibrosis is characterized by excessive deposition of extracellular matrix proteins and myofibroblast differentiation. Our previous findings have implicated resistin in cardiac fibrosis; however, the molecular mechanisms underlying this process are still unclear. Here we investigated the role of resistin in fibroblast-to-myofibroblast differentiation and elucidated the pathways involved in this process. Fibroblast-to-myofibroblast transdifferentiation was induced with resistin or TGFβ1 in NIH-3T3 and adult cardiac fibroblasts. mRNA and protein expression of fibrotic markers were analyzed by qPCR and immunoblotting. Resistin-knockout mice, challenged with a high-fat diet (HFD) for 20 weeks to stimulate cardiac impairment, were analyzed for cardiac function and fibrosis using histologic and molecular methods. Cardiac fibroblasts stimulated with resistin displayed increased fibroblast-to-myofibroblast conversion, with increased levels of αSma, col1a1, Fn, Ccn2 and Mmp9, with remarkable differences in the actin network appearance. Mechanistically, resistin promotes fibroblast-to-myofibroblast transdifferentiation and fibrogenesis via JAK2/STAT3 and JNK/c-Jun signaling pathways, independent of TGFβ1. Resistin-null mice challenged with HFD showed an improvement in cardiac function and a decrease in tissue fibrosis and reduced mRNA levels of fibrogenic markers. These findings are the first to delineate the role of resistin in the process of cardiac fibroblast-to-myofibroblast differentiation via JAK/STAT3 and JNK/c-Jun pathways, potentially leading to stimulation of cardiac fibrosis.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Fibroblast/myofibroblast differentiation; JAK2/STAT3; JNK/c-Jun; Myocardial fibrosis; Resistin; SP600125: JNK inhibitor; WP1066: JAK2 inhibitor

Mesh:

Substances:

Year:  2021        PMID: 33524540      PMCID: PMC8085100          DOI: 10.1016/j.phrs.2020.105414

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  56 in total

Review 1.  Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects.

Authors:  Begoña López; Arantxa González; Nerea Hermida; Félix Valencia; Eduardo de Teresa; Javier Díez
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-05-14       Impact factor: 4.733

2.  The opposing effects of CCN2 and CCN5 on the development of cardiac hypertrophy and fibrosis.

Authors:  Pyoung Oh Yoon; Min-Ah Lee; Hyeseon Cha; Moon Hee Jeong; Jooyeon Kim; Seung Pil Jang; Bo Youn Choi; Dongtak Jeong; Dong Kwon Yang; Roger J Hajjar; Woo Jin Park
Journal:  J Mol Cell Cardiol       Date:  2010-04-27       Impact factor: 5.000

Review 3.  Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart.

Authors:  Esther E Creemers; Yigal M Pinto
Journal:  Cardiovasc Res       Date:  2010-09-28       Impact factor: 10.787

4.  Fibroblast-Specific Genetic Manipulation of p38 Mitogen-Activated Protein Kinase In Vivo Reveals Its Central Regulatory Role in Fibrosis.

Authors:  Jeffery D Molkentin; Darrian Bugg; Natasha Ghearing; Lisa E Dorn; Peter Kim; Michelle A Sargent; Jagadambika Gunaje; Kinya Otsu; Jennifer Davis
Journal:  Circulation       Date:  2017-03-29       Impact factor: 29.690

5.  Resistin promotes cardiac hypertrophy via the AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) and c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathways.

Authors:  Soojeong Kang; Elie R Chemaly; Roger J Hajjar; Djamel Lebeche
Journal:  J Biol Chem       Date:  2011-04-08       Impact factor: 5.157

6.  Cardiac macrophage migration inhibitory factor inhibits JNK pathway activation and injury during ischemia/reperfusion.

Authors:  Dake Qi; Xiaoyue Hu; Xiaohong Wu; Melanie Merk; Lin Leng; Richard Bucala; Lawrence H Young
Journal:  J Clin Invest       Date:  2009-11-16       Impact factor: 14.808

7.  Bone Morphogenetic Protein 9 Reduces Cardiac Fibrosis and Improves Cardiac Function in Heart Failure.

Authors:  Kevin J Morine; Xiaoying Qiao; Sam York; Peter S Natov; Vikram Paruchuri; Yali Zhang; Mark J Aronovitz; Richard H Karas; Navin K Kapur
Journal:  Circulation       Date:  2018-07-31       Impact factor: 29.690

8.  Role of STAT3 in angiotensin II-induced hypertension and cardiac remodeling revealed by mice lacking STAT3 serine 727 phosphorylation.

Authors:  Fouad A Zouein; Carlos Zgheib; Shereen Hamza; John W Fuseler; John E Hall; Andrea Soljancic; Arnaldo Lopez-Ruiz; Mazen Kurdi; George W Booz
Journal:  Hypertens Res       Date:  2013-01-31       Impact factor: 3.872

9.  Resistin, adiponectin, and risk of heart failure the Framingham offspring study.

Authors:  David S Frankel; Ramachandran S Vasan; Ralph B D'Agostino; Emelia J Benjamin; Daniel Levy; Thomas J Wang; James B Meigs
Journal:  J Am Coll Cardiol       Date:  2008-12-26       Impact factor: 24.094

Review 10.  Association between serum resistin concentration and hypertension: A systematic review and meta-analysis.

Authors:  Yuxiang Zhang; Yixing Li; Lin Yu; Lei Zhou
Journal:  Oncotarget       Date:  2017-06-20
View more
  2 in total

1.  MiR-455-5p upregulation in umbilical cord mesenchymal stem cells attenuates endometrial injury and promotes repair of damaged endometrium via Janus kinase/signal transducer and activator of transcription 3 signaling.

Authors:  Dongyan Sun; Zhihe Jiang; Yanling Chen; Di Shang; Pan Miao; Jian Gao
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

2.  Calycosin as a Novel PI3K Activator Reduces Inflammation and Fibrosis in Heart Failure Through AKT-IKK/STAT3 Axis.

Authors:  Xiaoping Wang; Weili Li; Yawen Zhang; Qianbin Sun; Jing Cao; NanNan Tan; Shuangjie Yang; Linghui Lu; Qian Zhang; Peng Wei; Xiao Ma; Wei Wang; Yong Wang
Journal:  Front Pharmacol       Date:  2022-02-21       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.